SCHEMBL2375859

SCHEMBL2375859

COC(=O)C(Cn1ccnc1)N(Cc1ccc(-c2ccccn2)cc1)C(=O)C=Cc1ccc(C(F)(F)F)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP26A1 O43174 4/20 0.40
NOS3 P29474 4/20 0.39
NOS1 P29475 4/20 0.39
NOS2 P35228 4/20 0.39
TRPV1 Q8NER1 1/20 0.39
HTR5A P47898 2/20 0.38
CYP24A1 Q07973 1/20 0.36
HDAC1 Q13547 1/20 0.36
TRPM8 Q7Z2W7 1/20 0.36
HTR1A P08908 1/20 0.35
DRD2 P14416 1/20 0.35
DRD4 P21917 1/20 0.35
HTR1D P28221 1/20 0.35
HTR1B P28222 1/20 0.35
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
HTR7 P34969 1/20 0.35
ADRA1B P35368 1/20 0.35
DRD3 P35462 1/20 0.35
HTR2B P41595 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2375856 1.00 CYP26A1 (0.40) CYP26A1NOS3NOS1NOS2TRPV1
SCHEMBL2375108 0.93 NOS3 (0.42) NOS3NOS1NOS2TRPV1HTR5A
SCHEMBL2375102 0.93 NOS3 (0.42) NOS3NOS1NOS2TRPV1HTR5A
SCHEMBL2375100 0.93 NOS3 (0.42) NOS3NOS1NOS2TRPV1HTR5A
SCHEMBL2374882 0.91 CYP24A1 (0.39) TRPV1HTR5ACYP24A1HDAC1HTR1A
SCHEMBL2375592 0.87 NOS3 (0.44) NOS3NOS1NOS2TRPV1HTR5A
SCHEMBL2375583 0.87 NOS3 (0.44) NOS3NOS1NOS2TRPV1HTR5A
SCHEMBL2375587 0.87 NOS3 (0.44) NOS3NOS1NOS2TRPV1HTR5A
SCHEMBL2374204 0.87 NOS3 (0.40) NOS3NOS1NOS2TRPV1HDAC1
SCHEMBL2374202 0.87 NOS3 (0.40) NOS3NOS1NOS2TRPV1HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110224210-A1 NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS ACTELION PHARMACEUTICALS LTD. (CH) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224210-A1 NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS CTSA, BECN1, HDAC6 CYP26A1 2906/4885NOS3 783/4885NOS1 996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.